Santos Carolinne de Jesus Santos E, Fonseca Ricardo Roberto de Souza, Lima Sandra Souza, Carvalho Thais Mayara da Silva, das Mercês Letícia França, Avelino Maria Eduarda de Sousa, de Araújo Diogo Oliveira, Freitas Felipe Bonfim, Brasil-Costa Igor, Oliveira-Filho Aldemir Branco, Rosário Vallinoto Antonio Carlos, Machado Luiz Fernando Almeida
Biology of Infectious and Parasitic Agents Post-Graduate Program, Federal University of Pará, Belém 66075-110, PA, Brazil.
Virology Laboratory, Institute of Biological Sciences, Federal University of Pará, Belém 66075-110, PA, Brazil.
Vaccines (Basel). 2025 Mar 7;13(3):283. doi: 10.3390/vaccines13030283.
BACKGROUND/OBJECTIVES: The evaluation of the efficacy of COVID-19 vaccination in immunocompromised individuals, such as people living with HIV/AIDS (PLWH), still is of great global importance. The present study aimed to describe the presence of anti-SARS-CoV-2 IgG antibodies in PLWH vaccinated and unvaccinated against COVID-19 in the city of Belém, northern Brazil.
A cross-sectional study involving 510 PLWH was conducted from December 2021 to May 2022. Participants answered a sociodemographic questionnaire and subsequently underwent an anti-SARS-CoV-2 enzyme immunoassay for the detection of IgG antibodies, as well as quantification of CD4+ T lymphocytes and HIV-1 plasma viral load.
Most participants were male (70%), aged 25-50 years (72%), single (71.4%), and low-income (50.4%). The prevalence of anti-SARS-CoV-2 IgG antibodies was 94.3% (481/510), with most vaccinated individuals having received at least two doses of a COVID-19 vaccine. An association was observed between antibody levels and the number of vaccine doses, CD4+ T lymphocyte count, CD4+/CD8+ T lymphocyte ratio, and HIV-1 viral load.
PLWH developed high levels of antibodies against SARS-CoV-2 after receiving the vaccine, demonstrating that COVID-19 vaccination is of fundamental importance for the protection against severe COVID-19 in this specific group of immunocompromised individuals.
背景/目的：评估新冠病毒疫苗对免疫功能低下人群（如艾滋病毒/艾滋病感染者）的有效性在全球范围内仍具有重要意义。本研究旨在描述巴西北部贝伦市接种和未接种新冠病毒疫苗的艾滋病毒/艾滋病感染者中抗SARS-CoV-2 IgG抗体的存在情况。
2021年12月至2022年5月对510名艾滋病毒/艾滋病感染者进行了一项横断面研究。参与者回答了社会人口统计学问卷，随后接受了抗SARS-CoV-2酶免疫测定以检测IgG抗体，以及CD4+ T淋巴细胞定量和HIV-1血浆病毒载量检测。
大多数参与者为男性（70%），年龄在25至50岁之间（72%），单身（71.4%），低收入（50.4%）。抗SARS-CoV-2 IgG抗体的患病率为94.3%（481/510），大多数接种疫苗的个体至少接受了两剂新冠病毒疫苗。观察到抗体水平与疫苗接种剂量、CD4+ T淋巴细胞计数、CD4+/CD8+ T淋巴细胞比值和HIV-1病毒载量之间存在关联。
艾滋病毒/艾滋病感染者接种疫苗后产生了高水平的抗SARS-CoV-2抗体，表明新冠病毒疫苗接种对于保护这一特定免疫功能低下人群免受严重新冠病毒感染至关重要。
